glp-1 telehealth crackdown news today Last month, the FDA issued 25 warning letters to companies over what it called false or misleading claims about compounded medications. Read more at the link in the comments below FDA Issues Warning Letters to

M., Luis, P

Taken together, the figure highlights a key mechanistic principle underlying the therapeutic rationale for multi-agonist strategies: while GLP-1R monotherapy achieves meaningful metabolic and hepatic benefits exclusively through indirect, systemic pathways, the addition of GIPR and - most importantly - GCGR co-agonism introduces complementary and increasingly direct hepatic mechanisms, providing the pharmacological basis for the superior efficacy observed with dual and triple agonists in MASLD/MASH

Higher-dose semaglutide or tirzepatide use , doses under 2mg weekly are rarely implicated, while higher obesity-treatment doses show a clearer dose-dependent relationship

A healthier gut microbiome may support mood stability and better adherence to treatment over time

And the first GLP-1 agonist for obesity/weight loss was approved a full decade ago

Serious side effects could occur in rare cases, including pancreatitis or gallbladder problems